Study results published in Lupus Science & Medicine found that patients with lupus who were initially treated with medium or high doses of prednisone were likely to continue on higher doses, potentially putting them at risk for treatment-related complications. In contrast, patients given low doses for the first month were unlikely to be on medium or high doses later in the year.
"Glucocorticoids constitute one of the main therapies for systemic lupus erythematosus. However, despite their proven efficacy, oral glucocorticoids are important predictors of irreversible damage in lupus," the researchers wrote.
Read full story in MedPage Today.